Personalized mRNA Vaccines Could Significantly Reduce Risk of Melanoma Relapse

Moderna and Merck recently finished a phase 2 trial for personalized mRNA vaccines for melanoma patients. The vaccine uses genetic material from a person’s tumor to develop a vaccine that teaches a person’s immune system to identify cells that match that tumor, attacking those cells before they have a chance to grow.

Related Keywords

United States ,American ,Ravik Amaravadi ,Jeffreys Weber , ,York University Perlmutter Cancer Center ,Drug Administration ,American Association For Cancer Research ,American Association ,Cancer Research ,Annual Meeting ,Translational Research ,Penn Medicine ,Abramson Cancer Center ,Unique Case ,Every Time ,New York University ,Perlmutter Cancer Center ,